No filters selected
No filters selected
No filters selected
No filters selected
ESMO 2025: Data, decisions, and the future of oncology
The ESMO Congress 2025 once again demonstrated why it stands at the forefront of global oncology. Across five days in Berlin, the world’s leading clinicians, researchers, and pharmaceutical innovators gathered to reveal late-stage clinical data and discuss the future of cancer treatment. The event reaffirmed ESMO’s status as a defining moment in the oncology calendar - where new science meets strategic insight.
ESMO 2025: Hengrui’s immunotherapy combo shows perioperative benefit in HCC
The results strengthen Hengrui’s dominance in the Chinese market, showing camrelizumab and rivoceranib's potential beyond advanced disease.
ESMO 2025: Novartis’s Pluvicto delays progression to end-stage for mHSPC
The number of diagnosed prevalent drug-treated mHSPC cases in the 8MM will rise from 196,867 in 2025 to 244,101 by 2033.
ESMO 2025: Sichuan-Kelun moves in breast cancer ADC space
Sac-TMT will compete with two other TROP-2 targeted ADCs already approved: Gilead’s Trodelvy and AstraZeneca and Daiichi Sankyo’s Datroway.
ESMO 2025: Bayer and BI neck and neck in first line HER2+ NSCLC
Bayer and BI have reported broadly similar efficacy outcomes for sevabertinib and Hernexeos.
ESMO 2025: Merck KGaA's ADC leapfrogs to Phase III in colorectal cancer
Merck KGaA could now have a head start in the race to market Precem-TcT, which could become the first widely approved ADC in colorectal cancer.
ESMO 2025: Eli Lilly’s Verzenio extends survival in high-risk early breast cancer
These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.
ESMO 2025: Padcev/Keytruda combo has potential as new SOC for perioperative bladder cancer
The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.
ESMO 2025: J&J eyes Rybrevant indication expansion to HNSCC on Phase II victory
The bispecific’s efficacy and safety will now be explored through a Phase III trial in first-line HNSCC.
ESMO 2019: BMS’ CheckMate-227 results provide hope for double immunotherapy treatment of advanced NSCLC
Final data from BMS's Phase III CheckMate-227, Part 1 study was presented at the European Society of Medical Oncology conference in September.
GSK targets Syndivia’s prostate cancer ADC in £268m buy
Despite already having its own ADC in development for prostate cancer, GSK is doubling down on the modality.
Sensei to ditch its lead candidate and cut workforce amidst strategic review
The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.
MSD receives FDA approval for Keytruda combo to treat ovarian cancer
The approvals stem from the Phase III KEYNOTE-B96 trial data, which was presented at the 2025 ESMO Congress.
JP Morgan 2025: Moderna stock suffers after CEO reveals conservative 2025 guidance
CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.
China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway
China is becoming a global hub for oncology trials, offering access to a large and diverse patient population that can help speed recruitment, as well as expedited review pathways for INDs – but only sponsors who are ‘China ready’ will benefit.
ESMO 2019: IMpower-ing results from Roche’s Tecentriq in advanced non-small cell lung cancer
Results demonstrated that first-line treatment of patients with advanced non-small cell lung cancer and high programmed cell death ligand-1 expression who used Roche’s Tecentriq monotherapy resulted in improved overall survival compared with platinum-based chemotherapies.
ESMO25: Keytruda combo defies doubt, delivers PFS and OS gains in ovarian cancer
A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.
FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy
The approval relies on positive data from the POTOMAC Phase III trial.
MSD secures $700m for broad-cancer ADC asset
The funds will fuel continued Phase III clinical development of TROP-2 inhibitor sac-TMT.
Intismeran autogene a turning point for cancer vaccines
Intismeran autogene is fully personalised, as tissue from the resected tumour is sequenced to identify up to 34 mutations unique to that patient's cancer.